Vaxcyte, Inc.
PCVXVaxcyte is a clinical-stage biotechnology company utilizing its proprietary XpressCF cell-free protein synthesis platform to engineer high-fidelity vaccines against bacterial diseases.
Earnings
Next report
Nov 3, 2026 (in 3 months)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Vaxcyte is a clinical-stage biotechnology company utilizing its proprietary XpressCF cell-free protein synthesis platform to engineer high-fidelity vaccines against bacterial diseases. The company's core value proposition lies in its ability to develop broader-spectrum conjugate vaccines with enhanced immunogenicity by overcoming the limitations of conventional cell-based manufacturing, such as carrier suppression and random conjugation.
Vaxcyte is a clinical-stage innovator aiming to disrupt the established pneumococcal vaccine market by offering higher-valency candidates than current market leaders.
FAQ
- What is Vaxcyte, Inc.'s market cap?
- Vaxcyte, Inc. (PCVX) has a market capitalization of $8.1B and trades on NASDAQ.
- Who are Vaxcyte, Inc.'s competitors?
- Vaxcyte, Inc.'s key competitors include Moderna, Merck & Co., Inc., Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Vaxcyte, Inc. partner with?
- Vaxcyte, Inc.'s notable partners include Lonza, Sutro Biopharma, Inc., Thermo Fisher Scientific, and others.
- Where is Vaxcyte, Inc. headquartered?
- Vaxcyte, Inc. is headquartered in United States of America and employs approximately 254 people. It has been publicly traded since 2020.